A series of studies have demonstrated that administration of an NK3R antagonist (fezolinetant) leads to a reduction in LH secretion and attenuates symptoms of PCOS by reducing GnRH pulse generation (191). This evidence concerns the gene GNRH1 and polycystic ovary syndrome.